PDSB is expected to report earnings to rise 12.07% to -32 cents per share on March 27
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.10
Q1'24
Beat
by $0.07
Q4'23
Beat
by $0.09
The last earnings report on November 14 showed earnings per share of -28 cents, beating the estimate of -30 cents. With 3.35M shares outstanding, the current market capitalization sits at 82.84M.
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers